Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive February 1, 2012 Ben Comer	Best to Market Pharm Exec's Brand of the Year: Abbott's Humira
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool February 25, 2008 Brian Orelli	The Biologic That Keeps on Giving Just a month after Abbott Laboratories receives a fifth approval for its anti-inflammatory Humira, the FDA approved the biotech drug to treat yet another disease.
The Motley Fool January 22, 2008 Brian Orelli	The Little Anti-Inflammatory That Could Abbott Laboratories gets yet another approval for Humira, this time to treat chronic plaque psoriasis.
The Motley Fool May 11, 2011 Brian Orelli	Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good.
Pharmaceutical Executive December 1, 2011 Lujing Wang	The Payoff for Payers Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.
The Motley Fool June 22, 2011 Brian Orelli	In-Licensing to the Rescue Abbott's latest deal could help shore things up.
Chemistry World February 4, 2009 Matt Wilkinson	GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool July 15, 2009 Brian Orelli	Less Inflammation From Abbott's Quarter Humira is headed back in the right direction.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
Pharmaceutical Executive November 1, 2013 William Looney	Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
The Motley Fool November 21, 2007 Brian Lawler	Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note.
The Motley Fool February 10, 2004 David Nierengarten	The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market.
The Motley Fool January 24, 2008 Brian Orelli	Abbott Goes Global The drugmaker wraps up a solid 2007 with successful expansion overseas.
The Motley Fool April 8, 2005 David Nierengarten	The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
Managed Care June 2003 Thomas Morrow	The 'Heartbreak of Psoriasis' Has Met Its Match! New therapies that manipulate the immune system offer hope to patients and pose challenges to managed care.
The Motley Fool October 4, 2007 Brian Orelli	Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool July 23, 2007 Brian Lawler	A Setback for Elan and Biogen Elan and Biogen receive negative news about Tysabri. The EU medical authorities won't allow its use as a treatment for Crohn's disease.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool April 17, 2008 Brian Orelli	Abbott's Not Ailing Abbott produces double-digit growth; investors yawn.
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
Bio-IT World November 14, 2003 Kathy Ordonez	Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
Pharmaceutical Executive December 1, 2012 William Looney	2012: Year of Record The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry for good or bad in the year 2012.
Pharmaceutical Executive June 1, 2006 Nancy Dreyer	Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials.
American Family Physician August 15, 2003 Knutson et al.	Management of Crohn's Disease -- A Practical Approach - Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract that affects up to 480,000 persons in the United States. Symptoms include abdominal pain, diarrhea, fever, malaise, and arthralgias, and cause considerable morbidity.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Pharmaceutical Executive May 6, 2014 Ben Comer	The Brands of Yesteryear: Where Are They Now? We check back with previous Pharm Exec Brand of the Year winners like Januvia, Abbvie, and Gilenya to see how things are going.
American Family Physician February 1, 2005	Inflammatory Bowel Disease A patient handout on the intestinal disease, its causes, diagnosis and treatment options.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool May 15, 2006 Brian Gorman	AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note.
The Motley Fool August 1, 2007 Brian Lawler	Elan Gets a Vote of Confidence Elan receives some good news from an FDA advisory panel in the form of a recommendation to expand the use of Tysabri to treat Crohn's disease.
Fast Company Christina Farr	AHA, Alphabet Set Aside $75 Million To Cure Coronary Heart Disease The American Heart Association, Verily (the company formerly known as Google Life Sciences), and European pharmaceutical giant AstraZeneca are investing the funds over a five-year period.
Pharmaceutical Executive October 1, 2006 Rob Scott	Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug."
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
American Family Physician November 15, 2001 Edward R. Feller	Gynecologic Aspects of Crohn's Disease This article reviews the diverse gynecologic spectrum, protean manifestations and diagnostic difficulties of pelvic Crohn's disease...
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.